The global genotyping market size is anticipated to reach USD 46.53 billion by 2030, registering a CAGR of 14.59% over the forecast period, according to a new report by Grand View Research, Inc. Factors such as the rising prevalence of genetic diseases, rising awareness and research for personalized medicine, and increasing R&D funding for genomics research is expected to contribute to this growth.
Genotyping Market Report Highlights
- The reagents & kit segment accounted for the largest share of 61.77% in the market in 2022. This is attributed to increased demand for genetic testing, increased R&D spending, and increased genotyping testing volumes
- PCR segment dominated the market in 2022, whereas sequencing is expected to expand at the highest CAGR during the forecast period. This is due to advantages of the technique, such as low cost per sample, reduced bias as compared to arrays, comparative analysis across samples with no reference genome
- Pharmacogenomics is estimated to be the fastest-growing application segment during the forecast period due to increased usage of genotyping in drug development to reduce attrition of products in clinical development
- North America accounted for the largest market share in 2022, owing to proactive government measures, high disease prevalence, technological advancements, and advanced healthcare infrastructure
Gain deeper insights on the market and receive your free copy with TOC now @: Genotyping Market Report
Genotyping is the process of analyzing an individual’s genetic makeup or genotype. It involves examining specific regions of an individual’s DNA to identify variations or differences in the genetic code. Genotyping can be performed using various techniques, such as polymerase chain reaction (PCR), DNA sequencing, or microarray analysis. The applications of genotyping are diverse and have significant implications in various fields. In the field of medicine, genotyping plays a crucial role in personalized medicine and pharmacogenomics. By identifying specific genetic variations in patients, healthcare professionals can determine an individual’s susceptibility to certain diseases, predict treatment response, and prescribe medications that are most effective and safe based on their genetic profile.
Genotyping is also widely used in the field of genetic research. Scientists use genotyping to study the genetic basis of diseases, trace population migrations, and identify genetic markers associated with specific traits or conditions. It has been instrumental in advancing our understanding of human genetics and has contributed to the discovery of numerous disease-related genes. In agriculture and animal breeding, genotyping helps to improve crop yield, develop disease-resistant plants, and enhance livestock productivity. By identifying genetic markers associated with desirable traits, breeders can selectively breed plants or animals to achieve desired characteristics, leading to more efficient and sustainable agricultural practices.
Furthermore, genotyping plays a vital role in forensic science and paternity testing. DNA profiling, a type of genotyping, is used to establish identity, resolve criminal investigations, and determine biological relationships between individuals. Overall, genotyping has revolutionized our ability to understand and manipulate genetic information. Its applications span across medicine, research, agriculture, and forensic science, offering invaluable insights into human health, genetic diversity, and the development of tailored treatments and interventions.
Next-generation sequencing (NGS) technologies have significantly advanced genotyping capabilities by allowing the analysis of large volumes of genetic data at a reduced cost. This has led to more comprehensive genotyping studies and improved understanding of complex genetic variations. Traditional genotyping methods often involve analyzing DNA from a population of cells, which can mask genetic heterogeneity within individual cells. Single-cell genotyping techniques now enable the analysis of genetic variations at the level of individual cells, providing insights into cellular diversity, development, and disease progression. Genome-wide association studies (GWAS) have been instrumental in identifying genetic variations associated with complex diseases and traits. With the increasing availability of large-scale genomic datasets, researchers can conduct more extensive and powerful GWAS to uncover novel genetic markers and pathways related to various conditions.
Liquid biopsy involves analyzing genetic material, such as circulating tumor DNA (ctDNA), found in body fluids like blood. Genotyping techniques applied to liquid biopsy samples offer non-invasive and real-time monitoring of genetic changes in tumors, aiding in cancer diagnosis, treatment selection, and monitoring of treatment response. The revolutionary CRISPR-Cas9 gene-editing system has expanded beyond gene editing applications. It is now being used for genotyping purposes, such as detecting specific genetic variations and mutations. CRISPR-based genotyping techniques offer high specificity and sensitivity, allowing for precise and rapid analysis of genetic variations. Integrating genotyping data with other ‘omics’ technologies, such as transcriptomics, proteomics, and metabolomics, enables a more comprehensive understanding of the functional consequences of genetic variations. This integrative approach enhances our ability to link genotypes to phenotypes and uncover the underlying mechanisms of complex diseases.
Governments in multiple countries are taking various initiatives to provide support and funding to research organizations for personalized medicine, and genotyping research is anticipated to drive the market. For instance, in August 2019, NIH funded USD 4.6 million initial grants to Color, a health technology company, for precision medicine initiatives and development. Similarly, in 2018, the Government of Australia launched the Australian Genomics Health Futures Mission initiative. The government will provide USD 500 million over a period of 10 years for this mission, and the funding will be sourced from Medical Research Future Fund to improve the testing and diagnosis of genetic diseases and for the development of personalized medicine.
An increase in the prevalence of diseases such as cancer, Alzheimer’s disease, and Parkinson’s disease is another factor that is anticipated to drive demand for genotyping-based diagnostic testing. For instance, Roche has products such as Cobas HCV GT products for cervical cancer diagnosis. Additionally, 23&Me provides genetic testing for medical conditions, such as Parkinson’s disease and Alzheimer’s disease.
Failed clinical trials cost companies millions of dollars and therefore companies group patients according to their genotypes. Single Nucleotide Polymorphisms (SNP) based genotyping is increasingly being used in pharmacogenomics to study the effect of genetic variations on the difference in response to therapeutics. Genotyping-based treatment administration also helps in overall cost savings.
The COVID-19 pandemic increased the demand for genotyping-based research activities for the development of COVID diagnostics, vaccines, and therapeutics. Many companies, including Qiagen and Thermo Fisher Scientific, have now launched COVID-19 genotyping kits as a result of the growing demand.
For More Details or Sample Copy please visit link @: https://www.grandviewresearch.com/industry-analysis/genotyping-market/request/rs1
Genotyping Market Insights By Region
North America accounted for the largest market share, due to the increasing adoption of technologically advanced products, the presence of major pharmaceutical & biopharmaceutical companies, proactive government measures, and advances in healthcare infrastructure. Asia Pacific is anticipated to exhibit the fastest growth due to the presence of enormous untapped opportunities and increasing number of clinical trials being conducted in this region. This growth can also be attributed to other factors, such as technological advancements and the growing pharma and biopharma sector in the region.
Competitive Analysis By Major Players
Key players leverage strategic partnerships and new product launches to increase their product offerings. For instance, in January 2020, Illumina and Roche entered into a partnership for improving patient access to oncology genomic testing by assay development. Similarly, in June 2021, the Center for Aquaculture Technologies collaborated with Neogen Corporation to provide high-quality genotyping services tailored to aquaculture producers’ specific demands. Some of the prominent players in the global genotyping market include:
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN
- Hoffmann-La Roche Ltd.
- Fluidigm Corporation
- Danaher Corporation
Segmented the global genotyping market report based on product, technology, application, end-use and region.
Research Methodology
We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.
For Customized reports or Special Pricing please visit @: https://www.grandviewresearch.com/checkout/select-license/genotyping-market
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S. based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Contact:
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com